"I'm inclined to think this paves the way for a smooth transition should Teva elect not to proceed with the trial beyond the interim analysis stage"
Is this your view Madam ? Of course it is ..your so lightning quick at "analysis" ...you leave other commentators for dust.
The reason provided by our CEO is as follows:
"Targeting patients at high risk of HF-MACE and advanced heart failure could facilitate the shortest Phase 3 program, the fastest time to market, and the opportunity for the most attractive pricing".
Making a difference to the very high sick patients - is not a good reason ? (AND if that gets us to market earlier that would be a huge bonus to all Stakeholders ).
BUT your analysis/reason is of course "transitioning for Teva in case they pull out".
Something doesn't feel right here again ?
GLTAH
Timeframe for 2015, page-48
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.045(4.64%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 99.0¢ | $1.075M | 1.072M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 29104 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 64595 | 13 |
View Market Depth
| Last trade - 10.56am 04/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |